Full text is available at the source.
Isorhamnetin inhibits inflammatory response to alleviate DHEA-induced polycystic ovary syndrome in rats
Isorhamnetin reduces inflammation to ease hormone-related polycystic ovary symptoms in rats
AI simplified
Abstract
Isorhamnetin treatment significantly reduced serum levels of glucose, insulin, testosterone, and luteinizing hormone in DHEA-induced PCOS rats.
- DHEA-induced PCOS in rats resulted in increased levels of serum glucose, insulin, testosterone, and luteinizing hormone, while estradiol, sex hormone-binding globulin, and follicle stimulating hormone levels were decreased.
- The treatment led to increased body weight, ovary weight, and ovary volume, along with the presence of cystic follicles and a decrease in corpus luteum.
- Inflammatory levels and apoptosis in ovary tissues were higher in DHEA-induced PCOS rats, with activation of the tumor necrosis factor (TNF) signaling pathway.
- Isorhamnetin treatment decreased inflammatory factors and inhibited apoptosis in the ovary tissues of PCOS rats.
- After isorhamnetin treatment, levels of TNF receptor superfamily member 1 A, TNF-α, and FAS in ovary tissues were significantly reduced.
AI simplified